KRW 18200.0
(0.94%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 | -4.93 Billion KRW | -155.89% |
2022 | 8.82 Billion KRW | -41.64% |
2021 | 15.11 Billion KRW | -19.8% |
2020 | 18.84 Billion KRW | -43.19% |
2019 | 33.17 Billion KRW | -7.05% |
2018 | 35.69 Billion KRW | 3254.56% |
2017 | -1.13 Billion KRW | 93.12% |
2016 | -16.44 Billion KRW | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2024 Q2 | -2.17 Billion KRW | 39.37% |
2024 Q1 | -3.59 Billion KRW | 27.09% |
2023 FY | -4.93 Billion KRW | -155.89% |
2023 Q2 | -2.87 Billion KRW | 16.93% |
2023 Q3 | -6.78 Billion KRW | -135.72% |
2023 Q4 | -4.93 Billion KRW | 27.3% |
2023 Q1 | -3.46 Billion KRW | -139.26% |
2022 Q2 | 16.67 Billion KRW | 6.74% |
2022 FY | 8.82 Billion KRW | -41.64% |
2022 Q4 | 8.82 Billion KRW | -47.09% |
2022 Q3 | 16.67 Billion KRW | -0.05% |
2022 Q1 | 15.62 Billion KRW | 3.38% |
2021 Q3 | 14.26 Billion KRW | 0.0% |
2021 FY | 15.11 Billion KRW | -19.8% |
2021 Q4 | 15.11 Billion KRW | 5.99% |
2020 FY | 18.84 Billion KRW | -43.19% |
2019 FY | 33.17 Billion KRW | -7.05% |
2018 FY | 35.69 Billion KRW | 3254.56% |
2017 FY | -1.13 Billion KRW | 93.12% |
2016 FY | -16.44 Billion KRW | 0.0% |
Name | Net Debt | Net Debt Difference |
---|---|---|
HLB Pharmaceutical Co., Ltd | 18.96 Billion KRW | 126.004% |
CMG Pharmaceutical Co., Ltd. | 18.78 Billion KRW | 126.249% |
Celltrion Pharm, Inc. | 142.81 Billion KRW | 103.452% |
Huons Global Co., Ltd. | 13.26 Billion KRW | 137.17% |
DongKook Pharmaceutical Co., Ltd. | 44.19 Billion KRW | 111.157% |
Enzychem Lifesciences Corporation | -9.81 Billion KRW | 49.755% |
Humedix Co., Ltd. | -77.54 Billion KRW | 93.642% |
Boditech Med Inc. | -31.92 Billion KRW | 84.556% |
EuBiologics Co., Ltd. | 4.88 Billion KRW | 201.006% |
Huons Co., Ltd. | 73.9 Billion KRW | 106.671% |
BNC Korea Co., Ltd. | -67.65 Billion KRW | 92.712% |
AptaBio Therapeutics Inc. | -12.08 Billion KRW | 59.191% |